Premium
R‐COMP VS R‐CHOP AS FIRST‐LINE THERAPY FOR DIFFUSE LARGE B ‐CELL LYMPHOMA IN PATIENTS OLDER THAN 60 YEARS: RESULTS FROM A RANDOMIZED PHASE 2 STUDY FROM THE SPANISH GELTAMO GROUP
Author(s) -
Sancho J.,
Gual F.,
FernándezÁlvarez R.,
GonzálezGarcía E.,
Grande C.,
Gutiérrez N.,
Peñarrubia M.,
BatlleLópez A.,
GonzálezBarca E.,
Guinea J.,
Gimeno E.,
Peñalver F.,
Fuertes M.,
Gayoso J.,
HernándezRivas J.,
Moraleda J.,
García O.,
Martín A.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_47
Subject(s) - medicine , ejection fraction , cardiotoxicity , clinical endpoint , diffuse large b cell lymphoma , subclinical infection , doxorubicin , gastroenterology , heart failure , randomized controlled trial , urology , surgery , toxicity , lymphoma , chemotherapy
Hospital, Dordrecht, The Netherlands; Department of Hematology, Ankara University School of Medicine, Ankara, Turkey; Unit of Hematology, University Hospital of Amiens, Amiens, France; Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Área de Oncología, Unidad de Oncología Médica, E. P. Hospital Costa del Sol, Marbella, Spain; Hematology Unit, Santa Maria Delle Croci Hospital, Ravenna, Italy; Hematology Department, Ondokuz Mayis University, Samsun, Turkey; PDMA Operations (Biometrics), F. Hoffmann‐La Roche Ltd, Basel, Switzerland; Pharma Development Oncology, F. Hoffmann‐La Roche Ltd, Basel, Switzerland; Department of Internal Medicine I, University Hospital of Saarland, Homburg, Germany